Genzyme, Icahn Call Off Proxy Fight With Compromise Agreement
This article was originally published in The Pink Sheet Daily
Executive Summary
In exchange for withdrawing its proxy slate and agreeing to back Genzyme's nominees, Icahn Partners get two seats on biotech's board.